DL is an 8-year-old Mexican boy with a posterior atrial septal defect and partial anomalous pulmonary venous return of the right lower pulmonary vein with resultant right heart dilation with normal right ventricular systolic and diastolic function and no arrhythmias. Surgical repair was deferred, and DL's condition was being medically managed with furosemide 0.5 mg/kg BID and spironolactone 0.5 mg/kg BID.DL presents for developmental assessment due to poor performance in school following a lifting of COVID-19 pandemic restrictions and return to in-person classes. He has been attending full-time classes for 3 months without improvements in math, reading, and writing skills. Current attentional concerns at school include an inability to complete tasks without getting distracted by minimal stimuli and highly impulsive behavior.At the first assessment, DL was performing below grade expectations (e.g., reading by syllable without text comprehension, demonstrating preoperational addition and subtraction skills, inability to take dictation)-all of which was viewed as negatively impacted by attentional deficits. DL met DSM-5 criteria for ADHD, predominantly inattentive type. He was started on 10-mg immediate-release methylphenidate PO at 8 am with breakfast and a second dose of 10-mg immediate-release methylphenidate PO 4 hours after the first dose.After a month, at the first follow-up consultation, improvement in attention span, impulsivity, and school performance were observed, including reading skills and math proficiency. However, DL's mother raised concerns about circumoral cyanosis and acrocyanosis in the fingers of both hands after playing outside. These signs were not previously observed. During physical examination at the same visit, heart rate, blood pressure, and oximetry were within baseline ranges and his cardiac examination was unchanged. DL's dosage of methylphenidate was lowered to 10-mg immediate-release methylphenidate PO QD in the mornings with breakfast (8 am).DL did not return to clinic for another 2 months, having discontinued the medication after 2 months of treatment given financial limitations. His mother reported that DL's exertional circumoral cyanosis and acrocyanosis resolved while he was off medication. However, she observed an increase in inattentive symptoms and impulsivity and decline in his academic skills. She asked if our team was able continue the treatment despite the drug side effects, since she believed the benefits outweighed the disadvantages.Given these concerns, the team requested an updated cardiology assessment. The Cardiologist recommended discontinuation of methylphenidate and recommended follow-up with cardiothoracic surgery for reassessment of the surgical timeline.Given the limited treatment options in Mexico, what would you do next as the treating developmental-behavioral clinician…?

Download full-text PDF

Source
http://dx.doi.org/10.1097/DBP.0000000000001280DOI Listing

Publication Analysis

Top Keywords

10-mg immediate-release
12
immediate-release methylphenidate
12
circumoral cyanosis
8
cyanosis acrocyanosis
8
methylphenidate
5
complex adhd
4
adhd challenging
4
challenging case
4
case managing
4
managing co-occurring
4

Similar Publications

Pharmacokinetics of extended-release clarithromycin in patients with Mycobacterium ulcerans infection.

Sci Rep

August 2024

Department of Internal Medicine-Infectious Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Article Synopsis
  • Clarithromycin extended-release (CLA-ER) was tested alongside rifampicin (RIF) for treating Mycobacterium ulcerans in a WHO drug trial, but RIF can lower CLA serum levels due to its effect on metabolism.
  • The study involved 30 participants who provided dried blood samples over ten hours, with findings showing a non-significant decrease in CLA levels and a slight increase in systemic exposure compared to previous standard dosages.
  • Ultimately, CLA co-administration didn't impact RIF levels or effectiveness, leading to unclear benefits of CLA-ER over immediate release formulations.
View Article and Find Full Text PDF

Background: Two main types of galenic formulation, immediate release and prolonged release, have been developed to optimize melatonin bioavailability. We recently described the kinetic profile of a prolonged-release form generating a peak of plasma melatonin 1 h (T) after intake, followed by a prolonged decay over time. We have developed a new oral form of melatonin with the aim of producing a melatonin peak several hours after intake.

View Article and Find Full Text PDF

DL is an 8-year-old Mexican boy with a posterior atrial septal defect and partial anomalous pulmonary venous return of the right lower pulmonary vein with resultant right heart dilation with normal right ventricular systolic and diastolic function and no arrhythmias. Surgical repair was deferred, and DL's condition was being medically managed with furosemide 0.5 mg/kg BID and spironolactone 0.

View Article and Find Full Text PDF
Article Synopsis
  • * To gain regulatory approval for the MR microsphere, researchers needed to establish bioequivalence (BE) with the IR solution, which was achieved by conducting physiologically-based pharmacokinetic (PBPK) virtual BE trials instead of traditional clinical ones.
  • * The trials showed that the MR microsphere (10 mg once daily) is bioequivalent to the IR solution (5 mg twice daily) after both a single and multiple doses, highlighting a new method that minimizes unnecessary testing on healthy volunteers while aiding in drug formulation development.
View Article and Find Full Text PDF

Herein, we aimed to formulate a novel oral disintegrating tablet (ODT) of aripiprazole (ARP) capable of rapid disintegration using a direct compression technique. Different ODTs were fabricated with directly compressible excipients, and their disintegration time, wettability (water absorption ratio and wetting time), and mechanical properties (hardness and friability) were evaluated. The optimized ODT comprised F-Melt® type C, Prosolv® SMCC HD90, and Na croscarmellose (10 mg of ARP in a 130 mg tablet).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!